Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of K9 in Thyroid Eye Disease (TED)
NCT06467435Phase 1Terminated
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of kamlanoflast in thyroid eye disease (TED) (2 arms). Primary endpoints: Adverse Events at 26 weeks and Plasma concentrations of K9 at 24 hours. Started Nov 2024; status: terminated.
02
Drugs
kamlanoflast
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06467435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467435.